NASDAQ:GNTA Genenta Science Q4 2025 Earnings Results & Report $0.68 -0.05 (-6.51%) As of 02:29 PM Eastern This is a fair market value price provided by Massive. Learn more. Genenta Science beat analyst earnings expectations in its Q4 2025 results, released March 31, 2026. The company reported EPS of -$0.0750 versus the -$0.3641 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 31, 2026TimeBefore Market Opens Genenta Science EPS ResultsActual EPS-$0.0750Consensus EPS -$0.3641Beat/MissBeat by +$0.2891One Year Ago EPSN/AGenenta Science Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Genenta Science Q4 2025 Earnings FAQ Did Genenta Science beat earnings estimates for Q4 2025? Genenta Science (NASDAQ:GNTA) reported earnings of -$0.0750 per share for Q4 2025, beating the consensus estimate of -$0.3641. The report was announced on Tuesday, March 31, 2026. Genenta Science Earnings HeadlinesSòphia High Tech Flight Hardware on Board VEGA-C VV30 as the European Launcher Carries Sentinel-3C and FLEX into OrbitSeptember 15, 2026 | globenewswire.comGENENTA SCIENCE SPA: Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic ArmJuly 23, 2026 | finanznachrichten.deElon will prove them wrong againElon Musk's critics said self-driving cars were a pipe dream. Today, Tesla robotaxis carry passengers with no driver in major U.S. cities. Veteran tech investor James Altucher says Musk is applying the same playbook to a new project he calls his infinite money glitch, expected to launch October 21. Altucher, who has tracked tech breakthroughs for nearly four decades, calls this the biggest one he has ever covered.October 14 at 1:00 AM | Paradigm Press (Ad)Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic ArmJuly 23, 2026 | globenewswire.comGENENTA SCIENCE SPA: Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 ResultsJuly 22, 2026 | finanznachrichten.deGenenta-Backed Sòphia High Tech Reports Fiscal Year 2025 ResultsJuly 22, 2026 | globenewswire.comSee More Genenta Science Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Genenta Science? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genenta Science and other key companies, straight to your email. Email Address About Genenta ScienceGenenta Science (NASDAQ:GNTA) S.p.A. (NASDAQ: GNTA) is a clinical-stage biotechnology company developing cell and gene therapies for cancer. The company’s approach uses a patient’s own hematopoietic stem cells, genetically modified outside the body to produce therapeutic proteins and deliver them to the tumor microenvironment. Genenta’s lead investigational product, Temferon, is designed to generate interferon-alpha within solid tumors. The therapy is being studied primarily in glioblastoma, an aggressive form of brain cancer, with the goal of concentrating treatment in the tumor while limiting exposure to healthy tissues. Temferon is an investigational product and has not been approved for commercial use. Genenta was established in Italy as a spin-off of the San Raffaele Scientific Institute in Milan, building on research associated with Professor Luigi Naldini and his laboratory. The company is headquartered in Milan and has pursued clinical development internationally, including in the United States and Europe. Pierluigi Paracchi has been associated with the company’s founding and executive leadership.View Genenta Science ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
